Emepronium bromide (Cetiprin) as a postoperative spasmolytic agent in transvesical prostatectomy.
To find out whether Cetiprin reduces the vesical spasms seen after cystotomias, a double-blind investigation including 22 men was carried out. Eleven of the men were given 25 mg Cetiprin i.m. twice a day for 2 days after transvesical prostatectomy, then 200 mg orally 3 times a day the following 12 days. The rest of the men, 11 patients, received placebo. In the Cetiprin group 9 patients had no vesical spasm postoperatively, whereas 1 had moderate and 1 had severe spasms. Only 4 patients were without spasms in the control group, whereas 5 had moderate and 2 severe spasms. The postoperative reduction of the bladder volume were counteracted by Cetiprin. No significant influence on liver- or kidney function was seen with the dosages mentioned.
D000368:Aged; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004629:Emepronium / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics; D010919:Placebos; D011183:Postoperative Complications / Q000517:prevention & control*; D011468:Prostatectomy; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D013035:Spasm / Q000517:prevention & control; D001743:Urinary Bladder / Q000187:drug effects
D010276:Parasympatholytics; D010919:Placebos; D000644:Quaternary Ammonium Compounds; D004629:Emepronium; D003404:Creatinine